<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01980732</url>
  </required_header>
  <id_info>
    <org_study_id>NET0017</org_study_id>
    <secondary_id>26988</secondary_id>
    <nct_id>NCT01980732</nct_id>
  </id_info>
  <brief_title>68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors</brief_title>
  <official_title>68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrei Iagaru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and&#xD;
      monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors,&#xD;
      medullary thyroid cancer and other cancers expressing somatostatin receptors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Carcinoid Tumors</condition>
  <condition>Islet Cell (Pancreatic NET)</condition>
  <condition>Other Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-DOTA TATE</intervention_name>
    <description>Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than 18 years-old at the time of radiotracer administration&#xD;
&#xD;
          -  Provides written informed consent&#xD;
&#xD;
          -  Known diagnosis of NET or suspected SSTR positive tumors by 111In-Octreotide scan,&#xD;
             18FDG-PET, or MRI of the abdomen when clinically indicated&#xD;
&#xD;
          -  Karnofsky score greater than 50 or ECOG Performance Status 0-2&#xD;
&#xD;
          -  Women of childbearing age must have a negative pregnancy test at screening/baseline&#xD;
&#xD;
          -  Able to remain still for duration of each imaging procedure (about one hour)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years-old at the time of radiotracer administration&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Serum creatinine &gt;3.0 mg/dL&#xD;
&#xD;
          -  Hepatic enzyme levels more than 5 times upper limit of normal.&#xD;
&#xD;
          -  Use of any other investigational product or device within 30 days prior to dosing, or&#xD;
             known requirement for any other investigational agent prior to completion of all&#xD;
             scheduled study assessments.&#xD;
&#xD;
          -  Inability to lie still for the entire imaging time&#xD;
&#xD;
          -  Inability to complete the needed investigational and standard-of-care imaging&#xD;
             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)&#xD;
&#xD;
          -  Any additional medical condition, serious intercurrent illness, or other extenuating&#xD;
             circumstance that, in the opinion of the Investigator, may significantly interfere&#xD;
             with study compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University, School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrei Iagaru</investigator_full_name>
    <investigator_title>Assistant Professor of Radiology - Nuclear Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

